At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 215 enrolled
Drug / intervention
Duloxetine Hydrochloride +1 moredrug
Likely dose
Duloxetine Hydrochloride 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China
In Brief
A Phase 3 clinical trial evaluating Duloxetine Hydrochloride and Placebo for Diabetic Neuropathies. Completed, enrolled 215 participants across 7 sites.
Detailed Summary
To determine if duloxetine 60mg up to 120mg daily can work in treating pain from Diabetic Neuropathy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Neuropathies
CountriesChina
CollaboratorsBoehringer Ingelheim
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedDec 2006
Primary CompletionFeb 2008
TodayJul 2026
First PostedDec 8, 2006
Enrollment StartDec 1, 2006
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.6 years ago
Interventions
Duloxetine Hydrochloridedrug
60 mg every day (QD) (morning or evening), by mouth (PO)
Placebodrug
Placebo every day (QD), by mouth (PO)